



Cellular Therapy & Immunobiology Working Party

Chair: Annalisa Ruggeri
Secretary: Florent Malard
Vice-chair: Jürgen Kuball

Statistician: Jarl Mooyaart & Juana Schwartz
Study Coordinator Lead: Jorinde Hoogenboom
Data manager: Jeroen Knippenberg

CTIWP

The mission of the CTIWP is to understand and exploit the biological and immunological events occurring upon HSCT at large, and to implement modern cellular therapies (CTs) based on cell and gene engineering approaches to improve patient outcomes.

The CTIWP aims at fostering CT in Europe, through a continuous crosstalk between basic science findings, transplant immunobiology observations and implementation of CT approaches to answer unmet medical needs.


Educational events in 2025

- Joint CTIWP-ALWP educational meeting in Paris
- 7th EBMT/EHA European CAR T-Cell hybrid Meeting, Strasbourg
- Cell Therapy Day @EBMT2025

CELLULAR THERAPY in the REGISTRY

The Cellular Therapy Form was originally designed to collect data on stem cells, progenitors or mature cells, such as T-lymphocytes, unmanipulated, such as DLI, or sorted and/or cultured and/or genetically manipulated, such as CAR T-cells, used for treatment in combination with HSCT or alone, and including advanced therapeutic medicinal products (ATMP), as well as data on the clinical characteristics and outcomes of the patients. It has been revised with the primary focus on collecting data on CAR-T cells treated patient and adapted to the evolving IT now deployed to support the EBMT registry.

PLEASE CONTRIBUTE... AND REPORT YOUR PATIENTS



Source: EBMT Registry, February 2026

Data cutoff: 2026-02-05 17:20:00

KEY PUBLICATIONS 2025

The Use of MSC in Steroid-Refractory Acute GvHD in Europe: a Survey from the EBMT CTIWP Daenen L.G.M., et al. *BMT*

The Landscape of Immune Monitoring in CAR-T Cell Therapy: A Comprehensive Review and Survey Study by the CTIWP of the EBMT Pagliuca S., et al. *Blood reviews*

Current use of donor lymphocyte infusions after allogeneic stem cell transplantation in Europe: a survey on behalf of the CTIWP of the EBMT Santoro N., et al. *BMT*

CAR-T cell manufacturing failures and out-of-specification products in the real-world setting: A survey from the EBMT CTIWP Worel N., et al. *BMT*

Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee Greham C.E., et al. *The Lancet Oncology*

The future of viral vectors: A survey among Centers Associated with CTIWP of EBMT, NXTGEN Hightech, DARE-NL, T2EVOLVE, and GoCART Coalition Ramesh G., et al. *BMT*

Impact of the Addition of Antithymocyte Globulin to Post-Transplantation Cyclophosphamide in Haploidentical Transplantation with Peripheral Blood Compared to Post-Transplantation Cyclophosphamide Alone: A Retrospective Study on Behalf of the CTIWP-EBMT Capes A., et al. *British Journal of Haematology*

Use of bone marrow cells is associated with improved outcomes when compared to peripheral blood stem cell after haplo-identical transplants with post transplant cyclophosphamide, a study from of the CTIWP-EBMT Rocha V., et al. *BMT*

CTIWP at 52 Annual Meeting of EBMT

Cell Therapy Day	Monday, March 23, 9:00–17:45
CTIWP Session	Tuesday, March 24, 9:00–10:15
CTIWP Jon J. van Rood Award	Tuesday, March 24, 9:00–9:25
CTIWP Scientific Business Meeting	Tuesday, March 24, 12:45–14:00

Oral presentations

- Florent Malard - Real-world comparison of standard-of-care idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed/refractory multiple-myeloma: a study on behalf of the CTIWP and the CMWP of the EBMT
- Rafael de la Cámara - Impact Of CMV Infection In Patients With Lymphoma After CAR-T Therapy. An International Study On Behalf Of IDWP, LWP, and CTIWP Of EBMT
- Matteo Doglio - “Real world” incidence and characteristics of immune effector cell-associated hemophagocytic lymphohistiocytosis: a GoCART coalition study on behalf of the EBMT ADWP, CTIWP and TCWP
- Agnieszka Piekarska - Vaccination strategy in patients undergoing CAR-T therapies – an IDWP and CTIWP EBMT survey
- Giorgio Orofino - CAR-T activity for autoimmune diseases across EBMT centers in 2025: a survey on behalf of EBMT ADWP and CTIWP

ONGOING STUDIES

Use of regulatory T cells for GvHD prophylaxis and therapy in Europe (F. Simonetta)	Data collection
Current use of FMT in pediatric patients receiving hematopoietic stem cell transplantation and cellular therapies (R. Masetti)	Data collection
Outcomes after anti-BCMA CAR T-cells for multiple myeloma, a Retrospective analysis (F. Malard)	Analysis
Clinical Significance of the HLA-B Leader in Haploidentical Transplantation (E. Petersdorf)	Analysis
Impact of HLA mismatching on HCT outcome in the PTCy era, joint CTIWP – CIBMTR study (E. Arriata-Bolanos and S. Spellman)	Analysis
Real-World Use of Post-Transplant Cyclophosphamide (PTCy) for Graft-Vs-Host-Disease (GVHD) Prophylaxis in Transplant Centers (S. Elias)	Analysis
The impact of ex vivo Graft Engineering on GVHD Relapse Free Survival (M. de Witte)	Manuscript writing
Late effects and fertility after CAR-T cell therapy: a retrospective study on the behalf of the EBMT Cellular Therapy and Immunobiology working party (G. Orofino)	Manuscript submitted
Higher toxicity but improved outcomes after axicabtagene ciloleucel compared to tisagenlecleucel in patients aged >70 years with diffuse large b-cell lymphoma (V. Rocha)	Manuscript revisions

→ see all ongoing CTIWP studies on: <https://www.ebmt.org/research/studies>

FUTURE EVENTS

Joint CTIWP-LWP Educational Meeting | Heidelberg | 28-30 Oct 2026
9th EBMT/EHA European CAR T-Cell hybrid Meeting | Lisbon | 4-6 Feb 2027
[visit ebmt.org/events](https://www.ebmt.org/events) for more info

www.ebmt.org